TICKERNERD
Menu
ADPTADPTHealthcare · Diagnostics & Research

ADPT Stock Forecast: Adaptive Biotechnologies Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$25
+1.14% on the day

The 8 Wall Street analysts covering Adaptive Biotechnologies Corp. hold a median 12-month price target of $25 — +1.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$3.9B
Ticker Nerd rank
78 / 100
Median analyst target
$25
Analysts covering
8
Total return, dividends reinvested
1W
−0.8%
1M
+15.4%
YTD
+52.3%
1Y
+91.5%
From 52W high
−2.8%
From 52W low
+101.2%
$12
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ADPT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Adaptive Biotechnologies Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Growth
84
Quality
77
Revisions
76
Volatility
68
Accruals
60
Value
55
Size
27
Issuance
14

Momentum (95): The shares have been drifting up relative to others.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ADPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26ADPTHigh $28Median $25Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $21Median $25High $28

The green dot is the last close — the median target sits +1.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Aug 2026Piper SandlerMaintainsOverweight$20 → $28
30 July 2026BTIGMaintainsBuy$24 → $25
30 July 2026GuggenheimMaintainsBuy$22 → $25
30 July 2026Morgan StanleyMaintainsEqual-Weight$20 → $22
30 July 2026TD CowenMaintainsBuy$25 → $28
9 July 2026Morgan StanleyMaintainsEqual-Weight$18 → $20
9 July 2026Morgan StanleyMaintainsEqual-Weight—
29 June 2026GuggenheimMaintainsBuy—
17 June 2026BTIGReiteratesBuy—
12 May 2026Morgan StanleyMaintainsEqual-Weight—
6 May 2026BTIGReiteratesBuy—
6 May 2026GuggenheimReiteratesBuy—
6 May 2026JP MorganMaintainsOverweight—
6 May 2026TD CowenMaintainsBuy—
6 Feb 2026BTIGMaintainsBuy—
6 Feb 2026JP MorganMaintainsOverweight—
26 Jan 2026GuggenheimMaintainsBuy—
11 Nov 2025Morgan StanleyMaintainsEqual-Weight—
6 Nov 2025BTIGMaintainsBuy—
6 Nov 2025JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADPT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ADPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Adaptive Biotechnologies Corp. (ADPT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−63.5×

Cheaper than 99% of US stocks

Price / sales
12.8×

Cheaper than 12% of US stocks

Price / book
27.6×

Cheaper than 4% of US stocks

EV / EBITDA
−188.6×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
21.5%

Higher than 71% of US stocks

Earnings growth (YoY)
—
Gross margin
73.6%

Higher than 86% of US stocks

Operating margin
−22.0%

Higher than 21% of US stocks

Net margin
−20.7%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−38.8%

Higher than 24% of US stocks

Return on assets
−4.1%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ADPT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
ADPTAdaptive Biotechnologies Corp.$3.9B
78
BLLNBillionToOne, Inc.$4.4B
15
VCYTVeracyte, Inc.$3.3B
97
GRALGRAIL, Inc.$3.0B
36
SHCSotera Health Co.$5.4B
95
RDNTRadNet, Inc.$5.9B
34
CDNACareDx, Inc.$2.3B
100

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Adaptive Biotechnologies Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADPT news & analysis

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Seeking Alpha · 31 July 2026positive

Adaptive Biotechnologies is transitioning to a pure-play MRD diagnostics company through the planned spin-off of its Immune Medicine division. The company reported 49% year-over-year MRD revenue growth, sequencing gross margins above 70%, and a 14% adjusted EBITDA margin, while refinancing eliminated a 5% perpetual revenue burden.

Why it matters — For ADPT watchers, the shift to a pure-play MRD diagnostics company, combined with strong revenue growth and margin improvements, signals a potential inflection in the company's earnings profile and operational clarity.

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Zacks Investment Research · 31 July 2026neutral

Adaptive Biotechnologies (ADPT) reached a 52-week high, prompting Zacks Investment Research to examine the company's fundamentals to assess whether further gains are possible.

Why it matters — A 52-week high draws investor attention, and the article's focus on fundamentals offers insight into the financial health behind the stock price movement.

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 30 July 2026neutral

Adaptive Biotechnologies held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha.

Why it matters — The transcript provides ADPT investors and analysts with the full details of management's Q2 2026 financial results and business outlook.

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 30 July 2026neutral

Zacks reported on Adaptive Biotechnologies' Q2 2026 earnings, noting the company's top- and bottom-line results and comparing key metrics to Wall Street estimates and year-ago figures.

Why it matters — Investors tracking ADPT would follow this earnings recap to see how the company's core operational metrics stacked up against analyst expectations and prior-year performance.

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 29 July 2026positive

Adaptive Biotechnologies reported a Q2 loss of $0.10 per share, narrower than the Zacks Consensus Estimate of a $0.13 loss and an improvement from the $0.17 loss in the same quarter last year. Revenue exceeded expectations.

Why it matters — The narrower-than-expected loss and revenue beat indicate Adaptive Biotechnologies is outperforming analyst forecasts and showing year-over-year financial improvement.

FAQ

Frequently asked questions about ADPT stock

What is the ADPT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Adaptive Biotechnologies Corp. have a median 12-month price target of $25, with estimates ranging from $21 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADPT stock a buy right now?

Of the 8 analysts covering Adaptive Biotechnologies Corp., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adaptive Biotechnologies Corp. 78 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADPT?

As at 15 Aug 2026, Adaptive Biotechnologies Corp. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will ADPT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +1.1% from the last close, and Ticker Nerd's factor model ranks Adaptive Biotechnologies Corp. 78 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADPT stock forecast for 2030?

No analyst covering Adaptive Biotechnologies Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $28 over the next 12 months.

How has ADPT stock performed over the past year?

Adaptive Biotechnologies Corp. returned +91.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adaptive Biotechnologies Corp. do?

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that develops an immune medicine platform for diagnosing and treating various diseases. The company's core offering is its immunosequencing platform, which uses proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data that decodes the adaptive immune system.

What is the latest news on ADPT?

The most recent item we track (Seeking Alpha, 31 July 2026): "Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder". Adaptive Biotechnologies is transitioning to a pure-play MRD diagnostics company through the planned spin-off of its Immune Medicine division. The company reported 49% year-over-year MRD revenue growth, sequencing gross margins above 70%, and a 14% adjusted EBITDA margin, while refinancing eliminated a 5% perpetual revenue burden.

Company

About Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that develops an immune medicine platform for diagnosing and treating various diseases. The company's core offering is its immunosequencing platform, which uses proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data that decodes the adaptive immune system. Its primary diagnostic product is clonoSEQ, a test that detects and monitors minimal residual disease (MRD) in cancer patients by measuring remaining cancer cells during and after treatment. This capability is particularly valuable in hematology-oncology, where it helps optimize patient care and drug development across lymphoid cancers. The company also develops solutions in cellular therapy and vaccines. Headquartered in Seattle, Washington, Adaptive Biotechnologies serves clinical laboratories, pharmaceutical companies, and healthcare providers seeking to leverage immune system insights for improved patient outcomes and precision medicine applications.

CEO Mr. Chad M. Robins M.B.A. · 624 employees · United States · https://www.adaptivebiotech.com